课题基金 / 基金详情

Increase of the target inhibition effects on FLT3 based on the glycosylation and cellular localization status

Increase of the target inhibition effects on FLT3 based on the glycosylation and cellular localization status
基于糖基化和细胞定位状态增加对FLT3的靶点抑制效果
批准号:
21591198
负责人:
KIYOI Hitoshi
金额:
$2.83万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2009
资助国家:
日本
项目状态:
已结题
起止时间:
2009 至 2011

项目摘要

项目成果

KIYOI Hitoshi的其他基金

相似基金

相关文献

中文摘要
翻译
我们发现,糖基化机制的抑制降低了野生型Flt3的细胞表面表达,并通过抑制野生型Flt3表达细胞中激活的STATs而诱导了细胞死亡,而在表达突变的Flt3细胞中则没有。我们证明,在野生型Flt3中,糖基化是通过FL刺激自动磷酸化所必需的,而突变的Flt3在糖基化之前在细胞质内被自动磷酸化,从而通过STATS磷酸化导致细胞增殖。
英文摘要
We identified that the inhibition of glycosylation machinery reduced the cell surface expression of wild type FLT3 and induced cell death through the inhibition of activated STATs in wild type FLT3-expressing cells, but not in mutant FLT3-expressing cells. We demonstrated that the glycosylation is essential for auto-phosphorylation via FL-stimulation in wild type FLT3, and that mutant FLT3 is auto-phosphorylated within the cytoplasm before the glycosylation resulting in the cell proliferation via STATs phosphorylations.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Transcriptional Activity of MEF/ELF4 on the HDM2 Promoter Is Enhanced by the Mutation of the NPM1 Gene.
NPM1 基因突变增强了 MEF/ELF4 在 HDM2 启动子上的转录活性。
DOI: --
发表时间: 2010
期刊:
影响因子: --
作者: [Ando Koji, Matsuo Emi, Horio Kensuke, Tominaga Shinya, Imanishi Daisuke, Imaizumi Yoshitaka, Tsushima Hideki, Iwanaga Masako, Kiyoi Hitoshi, Naoe Tomoki, Miyazaki Yasushi]
通讯作者: Miyazaki Yasushi
DOI: 10.1182/blood-2011-01-329433
发表时间: 2011-08-11
期刊: BLOOD
影响因子: 20.3
作者: [Goto, Emi, Tomita, Akihiro, Naoe, Tomoki]
通讯作者: Naoe, Tomoki
FLT3/ITD Regulates Leukemia Cell Adhesion throughα4β1 Integrin and Pyk2 Signalin
FLT3/ITD 通过 α4β1 整合素和 Pyk2 信号蛋白调节白血病细胞粘附
DOI: --
发表时间: 2009
期刊:
影响因子: --
作者: [Katsumi A, Naoe T, et al.]
通讯作者: et al.
CMC-544(inotuzumab ozogamicin)shows less effect on multidrug resistant cells : analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma.
CMC-544(inotuzumab ozogamicin)对多重耐药细胞的影响较小:对 B 细胞慢性淋巴细胞白血病和淋巴瘤患者的细胞系和细胞进行分析。
DOI: --
发表时间: 2009
期刊: Br J Haemato 146
影响因子: --
作者: [Suzuki K, Nakase K, Kyo T, Katayama N, Akihiro Takeshita]
通讯作者: Akihiro Takeshita
52
    Analysis of ligand dependent resistance mechanism of RTK inhibitors
    • 批准号:
      24591387
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.41万
    • 财政年份:
      2012
    • 负责人:
      KIYOI Hitoshi
    • 依托单位:
    Analysis of the biojogicel effect of the nudeophcsmin gene mutation on development and progression of leukemia
    • 批准号:
      18591054
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.51万
    • 财政年份:
      2006
    • 负责人:
      KIYOI Hitoshi
    • 依托单位:
    Basic investigation for the development of a novel anti-leukemic therapy targeting to the mutant FLT3 molecule.
    • 批准号:
      14570973
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.3万
    • 财政年份:
      2002
    • 负责人:
      KIYOI Hitoshi
    • 依托单位:
    Analysis of the deregulation mechanism on cell growth and differentiation induced by mutant ELT3
    • 批准号:
      12670982
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.11万
    • 财政年份:
      2000
    • 负责人:
      KIYOI Hitoshi
    • 依托单位:
    海外基金